MLTX vs. SRPT, QGEN, PCVX, ASND, ROIV, RVMD, LNTH, BPMC, BBIO, and LEGN
Should you be buying MoonLake Immunotherapeutics stock or one of its competitors? The main competitors of MoonLake Immunotherapeutics include Sarepta Therapeutics (SRPT), Qiagen (QGEN), Vaxcyte (PCVX), Ascendis Pharma A/S (ASND), Roivant Sciences (ROIV), Revolution Medicines (RVMD), Lantheus (LNTH), Blueprint Medicines (BPMC), BridgeBio Pharma (BBIO), and Legend Biotech (LEGN). These companies are all part of the "pharmaceutical products" industry.
MoonLake Immunotherapeutics vs.
Sarepta Therapeutics (NASDAQ:SRPT) and MoonLake Immunotherapeutics (NASDAQ:MLTX) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, community ranking, profitability, dividends, valuation, analyst recommendations, earnings and media sentiment.
Sarepta Therapeutics presently has a consensus price target of $178.71, suggesting a potential upside of 51.45%. MoonLake Immunotherapeutics has a consensus price target of $84.29, suggesting a potential upside of 92.39%. Given MoonLake Immunotherapeutics' stronger consensus rating and higher possible upside, analysts plainly believe MoonLake Immunotherapeutics is more favorable than Sarepta Therapeutics.
In the previous week, Sarepta Therapeutics had 22 more articles in the media than MoonLake Immunotherapeutics. MarketBeat recorded 30 mentions for Sarepta Therapeutics and 8 mentions for MoonLake Immunotherapeutics. Sarepta Therapeutics' average media sentiment score of 0.72 beat MoonLake Immunotherapeutics' score of 0.49 indicating that Sarepta Therapeutics is being referred to more favorably in the media.
MoonLake Immunotherapeutics has lower revenue, but higher earnings than Sarepta Therapeutics. MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Sarepta Therapeutics, indicating that it is currently the more affordable of the two stocks.
Sarepta Therapeutics has a net margin of 7.43% compared to MoonLake Immunotherapeutics' net margin of 0.00%. Sarepta Therapeutics' return on equity of 11.00% beat MoonLake Immunotherapeutics' return on equity.
Sarepta Therapeutics has a beta of 0.77, indicating that its share price is 23% less volatile than the S&P 500. Comparatively, MoonLake Immunotherapeutics has a beta of 1.31, indicating that its share price is 31% more volatile than the S&P 500.
Sarepta Therapeutics received 1399 more outperform votes than MoonLake Immunotherapeutics when rated by MarketBeat users. However, 81.01% of users gave MoonLake Immunotherapeutics an outperform vote while only 75.33% of users gave Sarepta Therapeutics an outperform vote.
86.7% of Sarepta Therapeutics shares are owned by institutional investors. Comparatively, 93.9% of MoonLake Immunotherapeutics shares are owned by institutional investors. 7.7% of Sarepta Therapeutics shares are owned by company insiders. Comparatively, 12.0% of MoonLake Immunotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Summary
Sarepta Therapeutics beats MoonLake Immunotherapeutics on 10 of the 17 factors compared between the two stocks.
Get MoonLake Immunotherapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for MLTX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
MoonLake Immunotherapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:MLTX) was last updated on 1/20/2025 by MarketBeat.com Staff
